Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
ALX ONCOLOGY HOLDINGS INC (ALXO) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNDERWRITING AGREEMENT",
"ALX ONCOLOGY HOLDINGS INC. FORM OF WARRANT TO PURCHASE COMMON STOCK",
"Follow-On Public Offering of ALX Oncology Holdings Inc.",
"ALX Oncology Announces Pricing of Public Offering"
10/04/2023 8-K Results of Operations and Financial Condition  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
10/04/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer — Evorpacept is the first CD47 blocker to show activity in a global randomized study in solid tumors — Interim efficacy results showed the confirmed overall response rate for evorpacept combination treatment was 52% compared to 22% for control treatment — Company to host conference call and webcast today at 8:00 AM EDT"
08/10/2023 8-K Quarterly results
Docs: "ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update Advancing Phase 2/3 ASPEN-06 gastric cancer trial with data update expected in Q423 Terminating azacitidine combination development programs: ASPEN-02 in MDS and ASPEN-05 in AML Continuing focus on combinations with anti-cancer antibodies, antibody-drug conjugates, and PD-1/PD-L1 immune checkpoint inhibitors SOUTH SAN FRANCISCO, Calif., August 10, 2023 --"
05/11/2023 8-K Quarterly results
Docs: "ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights SOUTH SAN FRANCISCO, Calif., May 11, 2023 --"
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
03/09/2023 8-K Quarterly results
Docs: "ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones SOUTH SAN FRANCISCO, Calif., March 9, 2023 --"
11/29/2022 8-K Quarterly results
11/08/2022 8-K Quarterly results
10/31/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
Docs: "Investor Contact:"
04/12/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/28/2022 8-K Quarterly results
12/17/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Sales Agreement, by and among ALX Oncology Holdings Inc., Cantor Fitzgerald & Co., and Credit Suisse Securities (USA) LLC",
"Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation"
11/12/2021 8-K Quarterly results
Docs: ", Calif., November 11, 2021"
10/07/2021 8-K Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio"
08/27/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/12/2021 8-K Quarterly results
06/15/2021 8-K Quarterly results
05/17/2021 8-K Quarterly results
05/04/2021 8-K Quarterly results
03/25/2021 8-K Quarterly results
03/18/2021 8-K Quarterly results
03/15/2021 8-K Quarterly results
12/23/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 22, 2020 ALX ONCOLOGY HOLDINGS INC. Delaware 001-39386 85-0642577 File Number) Identification No.) 866 Malcolm Road, Suite 100 Burlingame, California 94010 Registrant's Telephone Number, Including Area Code: 466-7125 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 u..."
11/12/2020 8-K Quarterly results
Docs: "ALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational Highlights"
08/27/2020 8-K Quarterly results
07/21/2020 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy